Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer – Pipeline Review, H2 2016, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.
Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 42, 25, 3, 37 and 6 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.Small-Cell Lung Cancer.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Alchemia Ltd
Amgen Inc
Andarix Pharmaceuticals Inc
Aposense Ltd
Aprea AB
Astellas Pharma Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bayer AG
BeiGene Ltd
Beta Pharma Inc
BioLineRx Ltd
Bionomics Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corp
CellAct Pharma GmbH
Cellceutix Corp
Cerulean Pharma Inc
Cornerstone Pharmaceuticals Inc
Critical Outcome Technologies Inc
CytRx Corp
Double Bond Pharmaceutical International AB
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
G1 Therapeutics Inc
Genzyme Corp
GlaxoSmithKline Plc
Horizon Pharma Plc
Hutchison MediPharma Ltd
Immunomedics Inc
Incyte Corp
Johnson & Johnson
Karyopharm Therapeutics Inc
Kolltan Pharmaceuticals Inc
Kyowa Hakko Kirin Co Ltd
Lindis Biotech GmbH
MabVax Therapeutics Holdings Inc
MedImmune LLC
Medivation Inc
Merck & Co Inc
MolMed SpA
Mologen AG
NanoSmart Pharmaceuticals Inc
Nektar Therapeutics
Nippon Kayaku Co Ltd
Novartis AG
Omnitura Therapeutics Inc
OncoMed Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Oxford BioTherapeutics Ltd
Pfizer Inc
Pharma Mar SA
Polaris Pharmaceuticals Inc
Rexahn Pharmaceuticals Inc
SciTech Development, LLC
Spectrum Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Sunshine Biopharma Inc
Syros Pharmaceuticals Inc
Tarveda Therapeutics Inc
Tesaro Inc
Teva Pharmaceutical Industries Ltd
Verastem Inc
Vertex Pharmaceuticals Inc
Zensun (Shanghai) Sci & Tech Co Ltd
'
Table of Contents
Table of Contents 2
Introduction 6
Small-Cell Lung Cancer Overview 7
Therapeutics Development 8
Small-Cell Lung Cancer - Therapeutics under Development by Companies 10
Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 15
Small-Cell Lung Cancer - Pipeline Products Glance 16
Small-Cell Lung Cancer - Products under Development by Companies 19
Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes 27
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 28
Small-Cell Lung Cancer - Therapeutics Assessment 97
Drug Profiles 117
Small-Cell Lung Cancer - Dormant Projects 552
Small-Cell Lung Cancer - Discontinued Products 560
Small-Cell Lung Cancer - Product Development Milestones 562
Appendix 574
List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H2 2016 21
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H2 2016 22
Number of Products under Development by Companies, H2 2016 23
Number of Products under Development by Companies, H2 2016 (Contd..1) 24
Number of Products under Development by Companies, H2 2016 (Contd..2) 25
Number of Products under Development by Companies, H2 2016 (Contd..3) 26
Number of Products under Development by Companies, H2 2016 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H2 2016 28
Comparative Analysis by Late Stage Development, H2 2016 29
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Development, H2 2016 31
Products under Development by Companies, H2 2016 32
Products under Development by Companies, H2 2016 (Contd..1) 33
Products under Development by Companies, H2 2016 (Contd..2) 34
Products under Development by Companies, H2 2016 (Contd..3) 35
Products under Development by Companies, H2 2016 (Contd..4) 36
Products under Development by Companies, H2 2016 (Contd..5) 37
Products under Development by Companies, H2 2016 (Contd..6) 38
Products under Development by Companies, H2 2016 (Contd..7) 39
Products under Investigation by Universities/Institutes, H2 2016 40
Small-Cell Lung Cancer - Pipeline by 4SC AG, H2 2016 41
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016 42
Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2016 43
Small-Cell Lung Cancer - Pipeline by Alchemia Ltd, H2 2016 44
Small-Cell Lung Cancer - Pipeline by Amgen Inc, H2 2016 45
Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016 46
Small-Cell Lung Cancer - Pipeline by Aposense Ltd, H2 2016 47
Small-Cell Lung Cancer - Pipeline by Aprea AB, H2 2016 48
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2016 49
Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2016 50
Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 51
Small-Cell Lung Cancer - Pipeline by Bayer AG, H2 2016 52
Small-Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2016 53
Small-Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2016 54
Small-Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2016 55
Small-Cell Lung Cancer - Pipeline by Bionomics Ltd, H2 2016 56
Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 57
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 58
Small-Cell Lung Cancer - Pipeline by Celgene Corp, H2 2016 59
Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2016 60
Small-Cell Lung Cancer - Pipeline by Cellceutix Corp, H2 2016 61
Small-Cell Lung Cancer - Pipeline by Cerulean Pharma Inc, H2 2016 62
Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 63
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 64
Small-Cell Lung Cancer - Pipeline by CytRx Corp, H2 2016 65
Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 66
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2016 67
Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 68
Small-Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H2 2016 69
Small-Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2016 70
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 71
Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2016 72
Small-Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016 73
Small-Cell Lung Cancer - Pipeline by Immunomedics Inc, H2 2016 74
Small-Cell Lung Cancer - Pipeline by Incyte Corp, H2 2016 75
Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2016 76
Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 77
Small-Cell Lung Cancer - Pipeline by Kolltan Pharmaceuticals Inc, H2 2016 78
Small-Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 79
Small-Cell Lung Cancer - Pipeline by Lindis Biotech GmbH, H2 2016 80
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 81
Small-Cell Lung Cancer - Pipeline by MedImmune LLC, H2 2016 82
Small-Cell Lung Cancer - Pipeline by Medivation Inc, H2 2016 83
Small-Cell Lung Cancer - Pipeline by Merck & Co Inc, H2 2016 84
Small-Cell Lung Cancer - Pipeline by MolMed SpA, H2 2016 85
Small-Cell Lung Cancer - Pipeline by Mologen AG, H2 2016 86
Small-Cell Lung Cancer - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016 87
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H2 2016 88
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016 89
Small-Cell Lung Cancer - Pipeline by Novartis AG, H2 2016 90
Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016 91
Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 92
Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 93
Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2016 94
Small-Cell Lung Cancer - Pipeline by Pfizer Inc, H2 2016 95
Small-Cell Lung Cancer - Pipeline by Pharma Mar SA, H2 2016 96
Small-Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 97
Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 98
Small-Cell Lung Cancer - Pipeline by SciTech Development, LLC , H2 2016 99
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 100
Small-Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 101
Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma Inc, H2 2016 102
Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals Inc, H2 2016 103
Small-Cell Lung Cancer - Pipeline by Tarveda Therapeutics Inc, H2 2016 104
Small-Cell Lung Cancer - Pipeline by Tesaro Inc, H2 2016 105
Small-Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 106
Small-Cell Lung Cancer - Pipeline by Verastem Inc, H2 2016 107
Small-Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 108
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016 109
Assessment by Monotherapy Products, H2 2016 110
Assessment by Combination Products, H2 2016 111
Number of Products by Stage and Target, H2 2016 113
Number of Products by Stage and Mechanism of Action, H2 2016 120
Number of Products by Stage and Route of Administration, H2 2016 127
Number of Products by Stage and Molecule Type, H2 2016 129
Small-Cell Lung Cancer - Dormant Projects, H2 2016 565
Small-Cell Lung Cancer - Dormant Projects (Contd..1), H2 2016 566
Small-Cell Lung Cancer - Dormant Projects (Contd..2), H2 2016 567
Small-Cell Lung Cancer - Dormant Projects (Contd..3), H2 2016 568
Small-Cell Lung Cancer - Dormant Projects (Contd..4), H2 2016 569
Small-Cell Lung Cancer - Dormant Projects (Contd..5), H2 2016 570
Small-Cell Lung Cancer - Dormant Projects (Contd..6), H2 2016 571
Small-Cell Lung Cancer - Dormant Projects (Contd..7), H2 2016 572
Small-Cell Lung Cancer - Discontinued Products, H2 2016 573
Small-Cell Lung Cancer - Discontinued Products (Contd..1), H2 2016 574
List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H2 2016 21
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H2 2016 22
Number of Products under Development by Companies, H2 2016 23
Number of Products under Investigation by Universities/Institutes, H2 2016 28
Comparative Analysis by Late Stage Development, H2 2016 29
Comparative Analysis by Clinical Stage Development, H2 2016 30
Comparative Analysis by Early Stage Products, H2 2016 31
Assessment by Monotherapy Products, H2 2016 110
Assessment by Combination Products, H2 2016 111
Number of Products by Top 10 Targets, H2 2016 112
Number of Products by Stage and Top 10 Targets, H2 2016 112
Number of Products by Top 10 Mechanism of Actions, H2 2016 119
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 119
Number of Products by Routes of Administration, H2 2016 126
Number of Products by Stage and Routes of Administration, H2 2016 126
Number of Products by Top 10 Molecule Types, H2 2016 128
Number of Products by Stage and Top 10 Molecule Types, H2 2016 128
